Site and Mechanism(s) of Expiratory Airflow Limitation in COPD, Emphysema and Asthma-COPD Overlap
NCT03263130
This study is recruiting at 2 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this cross-sectional, observational study is to evaluate the site and mechanism(s) for expiratory airflow limitation in chronic, treated, current or former smokers (>15 pack years) with COPD, Emphysema, and Asthma-COPD Overlap with mild to severe expiratory airflow limitation. Treatment may include short and long acting inhaled beta2agonists, short and long acting inhaled muscarinic receptor antagonists, inhaled and or oral corticosteroid, oral antibiotic, supplemental oxygen, and PDE type 4 inhibitor.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- COPD, Emphysema, Asthma COPD Overlap
- Emphysema
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 30 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Gelb, Arthur F., M.D.
- Last updated on ClinicalTrials.gov
- October 27, 2023
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- Arthur F Gelb MD · Lakewood, CA
- Arthur F Gelb MD · Lakewood, CA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.